Market News & Trends
Aphios Granted US Patent for Improved Delivery of Targeted siRNA Using Nanotechnology
Aphios Corporation recently announced it has been granted United States Patent No. 9,981,238 titled Apparatus and Methods for Making Nanosomes Loaded with Nucleic Acids. The…
Lonza & Innosieve Diagnostics Announce Exclusive Distribution Agreement
Lonza Pharma & Biotech and Innosieve Diagnostics recently announced an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of…
FUJIFILM Cellular Dynamics Licenses University of California – Irvine’s Technologies
FUJIFILM Cellular Dynamics, Inc. (FCDI) recently announced it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation.
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
eFFECTOR Therapeutics, Inc. recently announced that it has dosed the first patient in the Phase 2 expansion portion of its monotherapy trial of eFT508, the company’s oral, small molecule inhibitor of MNK1/2, for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease From Oxford BioMedica; Announces Key Leadership Team Addition
Axovant Sciences recently announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain.
Immunomodulation Therapies Designed to Suppress Tumors & Fight Infection
Immunomodulation Inc. recently outlined its upcoming plans to advance its investigational product candidate, IMM-010, following consistent positive data from preclinical studies.
RedHill Biopharma Announces New US Patent for its Experimental Ebola Therapy
RedHill Biopharma Ltd. recently announced the United States Patent and Trademark Office (USPTO) has issued a patent covering RedHill’s proprietary experimental therapy for the treatment of Ebola virus disease. The patent is expected to be valid until 2035.
Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10
Aptevo Therapeutics Inc. recently announced the publication of preclinical data in Frontiers in Immunology highlighting the activity of APVO210 as a potent and selective immunosuppressive…
Elite Pharmaceuticals Announces Strategic Marketing Alliance With Glenmark Pharmaceuticals
Elite Pharmaceuticals, Inc recently announced the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals, Inc., USA to market two Elite generic products…
FDA Accepts Larotrectinib NDA & Grants Priority Review
Loxo Oncology, Inc. recently announced the US FDA has accepted the company’s New Drug Application (NDA) and granted Priority Review for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion
Amunix Announces Report by Bioverativ on Unprecedented Half-Life Obtained in Patients Treated With Novel, Long-Acting FVIII Utilizing XTEN Technology
Amunix Operating Inc. recently reported that Bioverativ (a Sanofi company) has announced preliminary Phase 1/2a safety and pharmacokinetic clinical data for BIVV001 (rFVIIIFc-VWF-XTEN), a novel and investigational factor VIII therapy for people with hemophilia A that incorporates Amunix’s XTEN technology to improve circulatory half-life.
Bioasis & WuXi Biologics Announce Initial Strategic Development & Manufacturing Collaboration
Bioasis Technologies, Inc.andWuxi Biologics recently announced an initial strategic collaboration for the development and manufacturing of xB3-001, Bioasis’ lead investigational biological candidate to treat brain cancer.
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM
MimiVax LLC recently announced positive interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (nGBM).
Nabriva Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Clinical Trial of Oral Lefamulin
Nabriva Therapeutics plc recently announced positive topline results from its Lefamulin Evaluation Against Pneumonia (LEAP 2) clinical trial, the second of two global, pivotal Phase 3 clinical trials of lefamulin. LEAP 2 evaluated the safety and efficacy of 5 days of oral lefamulin compared to 7 days of oral moxifloxacin in adult patients with moderate community-acquired bacterial pneumonia (CABP).
Beta Bionics Receives IDE Approval From the FDA to Begin a Home-Use Clinical Trial Testing the a New Bionic Pancreas System
Beta Bionics, Inc. recently announced it has received FDA approval to begin recruitment for home-use studies testing the insulin-only configuration of its iLet bionic pancreas system in a series of groundbreaking trials in adults and children with type 1 diabetes (T1D).
SYGNIS Completes Acquisition of TGR Biosciences
SYGNIS AG recently announced the completion of the acquisition of TGR Biosciences (TGR), the Australian research reagents company.
NanoBio Announces Corporate Name Change to BlueWillow Biologics & Closes $10-Million Financing
NanoBio Corporation recently announced it has changed its corporate name to BlueWillow Biologics in conjunction with the closing of a $10-million Series A financing.
Ardena Acquires Syntagon & Strengthens API Offering
Contract development and manufacturing organization (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.
Bellerophon Reaches Agreement With FDA on Study Design of Phase 2b Trial
Bellerophon Therapeutics, Inc. recently announced that, following the receipt of minutes from a recent meeting with the US FDA, the company has reached agreement with the FDA on all key aspects of its planned Phase 2b study of INOpulse for the treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD).
Flexion Therapeutics Presents Updated Results from Clinical Trial
Flexion Therapeutics, Inc. recently announced updated interim findings from its ongoing Phase 3b, open-label study to evaluate the overall safety and general tolerability of repeat administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with osteoarthritis (OA) of the knee.
